MedTrace Logo

Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache

NCT04353505 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2020-08-04

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of intra-arterial (IA) delivery of Dexamethasone and Ketorolac into the arteries supplying the sphenopalatine ganglion (SPG) - a collection of neurons that plays an important role in headache disorders - in patients with refractory migraine, cluster headache and trigeminal neuralgia. All patients must fail standard treatments prior to enrollment in the trial.

Conditions

  • Chronic Migraine
  • Cluster Headache
  • Trigeminal Neuralgia

Interventions

DRUG

Ketorolac

Intra-arterial delivery of Ketorolac in the internal maxillary artery, once

DRUG

Dexamethasone

Intra-arterial delivery of Dexamethasone in the internal maxillary artery, once.

Sponsors & Collaborators

  • Weill Medical College of Cornell University

    lead OTHER

Principal Investigators

  • Athos Patsalides, MD, MPH · WCMC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-31
Primary Completion
2022-06-30
Completion
2023-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04353505 on ClinicalTrials.gov